| Literature DB >> 28327875 |
Mayra Faria Novello1, Maria Luiza Garcia Rosa2, Ranier Tagarro Ferreira2, Icaro Gusmão Nunes2, Antonio José Lagoeiro Jorge1, Dayse Mary da Silva Correia3, Wolney de Andrade Martins1, Evandro Tinoco Mesquita1.
Abstract
BACKGROUND: : Hypertension is the most prevalent risk factor for cardiovascular disease, and its proper control can prevent the high morbidity and mortality associated with this disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28327875 PMCID: PMC5344658 DOI: 10.5935/abc.20170009
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Characteristics of the patients
| Characteristics | Individuals analyzed n (%) |
|---|---|
| Male | 103 (31.0) |
| Female | 229 (69.0) |
| 45 - 59 | 167 (50.3) |
| 60 - 69 | 90 (27.1) |
| ≥ 70 | 75 (22.6) |
| White | 108 (32.7) |
| Hybrid (Black/White) | 126 (38.2) |
| Black | 96 (29.1) |
| Never smoked | 168 (50.6) |
| Ex-smoker | 108 (32.5) |
| Smoker | 56 (16.9) |
| Yes | 24 (7.2) |
| No | 308 (92.8) |
| Sedentary | 77 (27.9) |
| Irregular | 40 (14.5) |
| Active | 140 (50.7) |
| Very active | 19 (6.9) |
| BMI < 26 (ideal weight) | 106 (32.1) |
| BMI 26 - 29.99 (overweight) | 104 (31.5) |
| BMI ≥ 30 | 120 (36.4) |
| Yes | 107 (32.2) |
| No | 225 (67.8) |
BMI: body mass index.
The color was not informed by two individuals.
The level of physical activity was not verified in 56 individuals.
The BMI (kg/m2) was not evaluated in two individuals.
Main prescribed medications (n=332)
| Name | N (%) |
|---|---|
| 209 (63.0) | |
| Hydrochlorothiazide | 178 (53.7) |
| Furosemide | 16 (4.8) |
| Chlorthalidone | 10 (3.0) |
| Spironolactone | 3 (0.9) |
| Indapamide | 2 (0.6) |
| 192 (57.8) | |
| Enalapril | 108 (32.5) |
| Captopril | 81 (24.4) |
| Lisinopril | 1 (0.3) |
| Ramipril | 1 (0.3) |
| Cilazapril | 1 (0.3) |
| 89 (26.8) | |
| Atenolol | 53 (16.0) |
| Propranolol | 27 (8.1) |
| Carvedilol | 7 (2.1) |
| Metoprolol | 1 (0.3) |
| Bisoprolol | 1 (0.3) |
| 84 (25.3) | |
| Amlodipine | 41 (12.3) |
| Nifedipine | 37 (11.2) |
| Diltiazem | 4 (1.2) |
| Verapamil | 1 (0.3) |
| Lercanidipine | 1 (0.3) |
| 61 (18.4) | |
| Losartan | 52 (15.7) |
| Valsartan | 9 (2.7) |
| 14 (4.2) | |
| Clonidine | 8 (2.4) |
| Hydralazine | 4 (1.2) |
| Aliskiren | 1 (0.3) |
| Methyldopa | 1 (0.3) |
ACEi: angiotensin-converting enzyme inhibitors; BB: beta-blockers; CCB: calcium channel blockers; ARB: angiotensin receptor blockers.
Main associations of medications (n=332)
| Type of therapy | Prescriptions | Diuretics | ACEi | BB | CCB | ARB |
|---|---|---|---|---|---|---|
| Monotherapy | 115 (34.6) | 25 (21.7) | 61 (53.0) | 8 (7.0) | 7 (6.1) | 14 (12.2) |
| Dual therapy | 136 (41.0) | 112 (41.6) | 85 (31.6) | 30 (11.2) | 24 (8.9) | 18 (6.7) |
| Triple therapy | 60 (18.1) | 50 (28.8) | 34 (19.5) | 34 (19.5) | 35 (20.1) | 21 (12.1) |
| > 3 medications | 21 (6.3) | 21 (27.6) | 12 (15.8) | 17 (22.4) | 18 (23.7) | 8 (10.5) |
ACEi: angiotensin-converting enzyme inhibitors; BB: beta-blockers; CCB: calcium channel blockers; ARB: angiotensin receptor blockers.
Main non-compliances encountered
| Prescribed | Total | Underdosing | Overdosing | Underfrequency | Overfrequency | Triple therapy | Wrong |
|---|---|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Diuretics | 11 (16) | 0 | 0 | 0 | 2 (18) HCTZ | 8 (73) | 1 (9) HCTZ + |
| ACEi | 20 (29) | 1 (5) Enalapril | 0 | 10 (50) Captopril | 3 (15) Enalapril | - | 6 (30) ACEi + |
| BB | 15 (21.7) | 3 (20) PPL | 0 | 3 (20) Carvedilol | 2 (13) Atenolol | - | - |
| CCB | 18 (26.1) | 3 (16.7) Nifedipine | 4 (22.2) | 8 (44.4) Nifedipine | 0 | - | - |
| ARB | 0 | 0 | 0 | 0 | 0 | - | ARB + ACEi |
| Other | 5 (7.2) | 2 (40) Hydralazine | 0 | 2 (40) Hydralazine | 0 | - | 1 (20) Clonidine + |
| TOTAL | 69 (100) | 12 (17.4%) | 4 (5.8%) | 30 (43.5%) | 7 (10.1%) | 8 (11.6%) | 8 (11.6%) |
ACEi: angiotensin-converting enzyme inhibitors; BB: beta-blockers; CCB: calcium channel blockers; ARB: angiotensin receptor blockers; PPL: propranolol; HCTZ: hydrochlorothiazide.
The association ACEi + ARB (six prescriptions) was counted only once, although it was described as non-compliant in regards to ACEi and ARB.
Relationship between BP control and prescription compliance according to cut-off points
| BP < 140 / 90 mmHg | BP < 140 / 90 mmHg | |||||
|---|---|---|---|---|---|---|
| C | NC | p | C | NC | p | |
| Prescription | N(%) | N(%) | 0.75 | N(%) | N(%) | 0.6 |
| Non-compliant | 24 (16.1) | 40 (21.9) | 22 (17.2) | 42 (20.6) | ||
| Compliant | 125 (83.9) | 143 (78.1) | 106 (82.8) | 162 (79.4) | ||
| Total | 149 (44.9) | 183 (55.1) | 128 (38.6) | 204 (61.4) | ||
C: controlled; NC: not controlled; p: p-value (Pearson’s chi-square test).